Sandra G. Stoneman is co-head of the firm's Life Sciences Practice Group and also serves on the firm's Inclusion Committee. Ms. Stoneman focuses on advising emerging growth companies and venture capital and private equity investors in the life sciences and technology industries. Ms. Stoneman works with her clients in matters relating to forming companies, structuring and negotiating financing, issues of corporate governance, licensing agreements, joint ventures and other strategic transactions, as well as mergers, acquisitions and divestitures.
In 2008, Ms. Stoneman was selected as a Lawyer on the Fast Track by The Legal Intelligencer. She also was named a Pennsylvania Rising Star in 2005, 2006 and 2007. Rising Stars are chosen by their peers as being among the top up-and-coming Pennsylvania lawyers.
Ms. Stoneman is a 1997 magna cum laude graduate of Temple University School of Law, where she was an articles editor for the Temple Law Review, and is a summa cum laude graduate of the State University of New York at Binghamton.
Honors & Awards
•Named one of Pennsylvania's Lawyers on the Fast Track by The Legal Intelligencer, August 2008
•Named a Super Lawyer Rising Star by the publishers of Law and Politics magazine, 2005-2007
•Judicial and Congressional Back-Door Methods that Limit the Effect of Roe v. Wade, 70 Temple Law Review 633, 1997
Selected Speaking Engagements
•Panelist, Pharmaceutical Consulting Consortium International Meeting, February 2014
•Frequent lecturer at The Women's Business Development Center JumpStart panel programs
•Panelist, Power of Persuasion event hosted by Entrepreneurs' Forum, May 2008
•Speaker, Choice of Entity, Wharton Venture Initiation Program Presentation, February 2008
•Panelist, How to Become Fundable, lunch panel discussion at New Jersey Technology Council Venture Fair, March 2006
|Reported Cases||Representative Matters; Represented Gliknik Inc., a privately held biopharmaceutical company, in negotiating an exclusive worldwide license agreement with Pfizer Inc. for Gliknik's recombitant stradomer GL-2045, a drug candidate designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). Gliknik received an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments and tiered, double-digit royalties on net sales of any products commercialized under the license agreement. Represented Bioconnect Systems, Inc., a medical device firm, in raising $9.1 million in a private stock sale. Advised ADFLOW, Inc. on corporate and healthcare issues (corporate practice of medicine, advertising, FDA) for their patented technology platform that provides consumer-oriented healthcare solutions and offers advanced digital signage capabilities. Also provided advice regarding general corporate and securities matters, capital raising, strategic relationships and labor and employment matters. Represented EyeIC, Inc., a start-up company that provides web-based FDA-approved eye image comparison technology to support clinical care, patient education, claims submission and documentation, in connection with its general corporate and securities matters, capital raising efforts, strategic relationships and labor and employment matters. Represented Celator Pharmaceuticals, Inc., a New Jersey-based firm specializing in cancer drugs, in a $32.5 million private placement led by Valence Life Sciences. Represented a manufacturer of integrated ultrasound imaging systems in its acquisition by a healthcare company. Represented Pennsylvania dermatology company in raising over $20 million from investors, including prominent venture capital firms, through a preferred stock offering. Represented Multimodal Technologies, Inc. in the sale of 100 percent of its outstanding equity securities in a reverse triangular merger to Miami Acquisition Corp., a wholly owned subsidiary of Medquist Holdings, Inc. (NASDAQ:MEDH), for an aggregate purchase price of approximately $130 million, including approximately $50 million in cash at closing, approximately $50 million in Medquist common stock at closing, and approximately $30 million of deferred payments payable in three annual installments. Represented Iroko Holdings S.A. (Luxembourg) in its acquisition of iCeutica Inc. (Australia), a nanotechnology platform company, for an undisclosed amount. Represented an early-stage company engaged in the business of addressing small molecule drug discovery challenges in its $1.7 million convertible note financing. Financing was secured from existing investors. Represented Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's healthcare products, in its $45 million Series B preferred stock financing. The financing, which was completed in May and June of 2010, was co-led by Investor Growth Capital and Care Capital, with strong participation from ProQuest Investments. Closed a deal on behalf of Anchor Inne, Inc. to sell the assets of a traumatic brain-injury center it owned and operated in Western Pa., to a nationally well-known owner/operator of nursing homes, assisted living centers and similar facilities. In addition, as part of this transaction, Anchor Inne, through a related entity, West Lake Associates, leased the real estate on which the center is located to the asset buyer. Represented Protez Pharmaceuticals, Inc. in two rounds of Preferred Stock financing from venture capital investors and its acquisition by Novartis Pharmaceuticals Corporation, a structured acquisition with a $100 million up-front payment. Counsel to Protez Pharmaceuticals in venture capital financings and business initiatives for several years prior to its sale. Assisted a medical diagnostic company in securing in excess of $20 million in preferred stock financing from venture capital investors; Trion Group, Inc., a company engaged in the business of providing employee benefits services, acquired the assets of Wink Benefits & Communications, a company engaged in the business of voluntary employee benefits products brokerage. Represented AMETEK, Inc., a manufacturer of electronic instruments and electromechanical devices, through a wholly owned subsidiary, when it acquired the assets of B&S Aircraft Parts & Accessories, a company engaged in the business of providing maintenance, repair and overhaul services to the business jet, light jet and helicopter markets utilizing the assets. Represented AMETEK, Inc., a global manufacturer of electronic instruments and electromechanical devices, through a wholly owned subsidiary, acquired the assets of Advanced Industries, Inc., a company engaged in the business of designing, manufacturing, repairing, rewinding and selling electrical motors and generators. VGX Pharmaceuticals, Inc., a biopharmaceutical company that develops products for the treatment of infectious diseases, cancer and inflammatory diseases, purchased the assets of ADViSYS, Inc., including its technology relating to DNA delivered therapeutics and delivery systems. Represented biopharmaceutical company Ception Therapeutics, Inc. in several transactions, including its $77 million Series C financing and its acquisition by Cephalon, Inc. for $250 million and up to $500 million in milestone payments. Represented an ophthalmic drug development company in its $22 million Series C preferred stock financing. Represented a public company manufacturer of electric motors and electronic instruments with worldwide operations in its $67.4 million acquisition in the U.S. and Italy of a leading designer and manufacturer of engineered motors. Represented a transdermal contraceptive patch developer in its $18 million preferred stock financing. Counsel to a start-up pharmaceutical company in its licensing agreement from the University of Chicago. Also represent the client in an ongoing search for its seed round of venture capital financing to enable it to commercialize preventative treatments for necrotizing enterocolitis and inflammatory bowel disease. Represented medical device company in its $12 million issuance and sale of stock to one of the largest U.S. pharmaceutical companies. In addition, the pharmaceutical company paid an additional $3 million to the stockholders of the medical device company to acquire options to acquire the remaining outstanding shares from the stockholders, the purchase price of which, if the options are exercised, would be worth $45 million, plus the potential to receive significant additional contingent consideration. Counsel to Celator Pharmaceuticals, Inc. (NASDAQ - CPXX), which is developing oncology drugs, in transitioning from a venture-financed company to a public company and raising more than $125 million in several rounds of financing from venture capital and other accredited investors since 2005. Celator evolved from technology developed at the British Columbia Cancer Agency and maintains a subsidiary in Vancouver, British Columbia. The Series B round included a completed cross-border restructuring. After subsequent venture financings, we represented Celator in attaining status as a public company through a Form 10 filing, followed by a $39.3 million private placement led by Valence Life Sciences. Represented a major French CAC 40 company in connection with a complete reorganization of the worldwide holdings of a U.S. subsidiary in order to enable the divestiture of two divisions to separate buyers. Counsel to the lead venture capital investor in a private placement of approximately $16 million in capital stock of Acuity Pharmaceuticals, Inc.. Acting for Othera Pharmaceuticals, Kennett Square, PA. Othera is developing drugs for ophthalmic indications and we just assisted them in raising $15 million in Series B venture capital financing. The investors were Johnson & Johnson Development Corp., New Spring Ventures, Commerce Health Ventures and Liberty Ventures. Represented Ceptaris Therapeutics in its acquisition by Actelion for $250 million cash plus undisclosed milestone payments and sales earnouts. Represented Marinus Pharmaceuticals, Inc., a neuroactive steroid developer, in its $21 million Series C financing from U.S. venture capital firm Domain Associates, LLC, Russian state-owned investment fund RusnanoMedInvest, and co-investors Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. Counsel to emerging businesses in structuring, negotiating and drafting venture capital and other private equity financing arrangements and related corporate governance, executive compensation, and securities law compliance issues. Counsel to technology and life science companies in the structure, negotiation and drafting of various types of licensing and other technology agreements, and joint venture arrangements. Counsel to buyers and sellers in domestic and cross-border acquisition and divestiture transactions, including assistance with structuring transactions from business, regulatory and tax perspectives. Counsel to public companies in connection with securities regulation, reporting and financing activities. Counsel to private equity funds in structuring and making investments in portfolio companies and real estate transactions and preparing offering materials and complying with securities laws in connection with capital raising transactions.|